Systematic review and meta-analysis of currently available clinical evidence on migraine and patent foramen ovale percutaneous closure: Much ado about nothing?

Catheterization and Cardiovascular Interventions

Volumn 75, Issue 4, 2010, Pages 494-504

  Butera, Gianfranco ^a   Biondi Zoccai, Giuseppe G L ^b   Carminati, Mario ^a   Caputi, Luigi ^c   Usai, Susanna ^c   Bussone, Gennaro ^c   Meola, Giovanni ^a   Delogu, Angelica Bibiana ^d   Sheiban, Imad ^b   Sangiorgi, Giuseppe ^e  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Meta analysis; Migraine; Patent foramen ovale; Stroke; Transcatheter closure

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE; TRYPTOPHAN DERIVATIVE; WARFARIN;

CARDIOVASCULAR EQUIPMENT; CATHETERIZATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MIGRAINE; PATENT FORAMEN OVALE; REVIEW; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADULT; AGED; EVIDENCE-BASED MEDICINE; FEMALE; FORAMEN OVALE, PATENT; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RISK ASSESSMENT; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 77950527418     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22232     Document Type: Review

References (41)

1. Rasmussen BK, Jensen R, Schroll M, Olsen J. Epidemiology of headache in a general population-A prevalence study. J Clin Epidemiol 1991;44:1147-1157.
2. Lipton RB, Silberstain SD, Stewart WF. An update on migraine epidemiology. Headache 1994;34:319-328.
3. IHS (International Headache Society). Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain of the headache classification committee of the IHS. Cephalagia 2004;24 (suppl 1):32-33.
4. Agostoni E, Fumagalli L, Santoro P, Ferrarese C. Migraine and stroke. Neurol Sci 2004;25(S3):S123-S125.
5. Del Sette M, Angeli S, Leandri M, Ferriero G, Bruzzone GL, Finocchi C, Gandolfo C. Migraine with aura and right-to-left shunt on transcranial Doppler: A case-control study. Cerebrovasc Dis 1998;8:327-330. (Pubitemid 28491093)
6. Anzola GP, Magoni M, Guineani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: A transcranial Doppler study. Neurology 1999;52:1622-1625. (Pubitemid 29220637)
7. Lamy C, Giannesini C, Zuber M, Arquizan C, Meder JF, Trystram D, Coste J, Mas JL. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen OVALE: The PFO-ASA Study. Atrial septal aneurysm. Stroke 2002;33:706-711.
8. Post MC, Letterboer TGW, Mager JJ, Plokker TH, Kelder JC, Westermann CJJ. A pulmonary right-to-left shunt in patients with hereditary hemorrhagic teleangiectasia is associated with an increased prevalence of migraine. Chest 2005;128:2485-2489.
9. Schwedt TJ, Dodick DW. Patent foramen ovale and migraine-Bringing closure to the subject. Headache. 2006;46:663-671.
10. Post MC, Luermans JG, Plokker HW, Budts W. Patent foramen ovale and migraine. Catheter Cardiovasc Interv 2007;69:9-14.
11. Stroup DF, Berlin JA, Morton SC, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
12. Guyatt G, editor. Users' Guide to the Medical literature. A manual for Evidence Based Clinical Practice. Chicago: AMA Press; 2002.
13. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Versions 4.2.6. John Wiley & Sons, Inc. Hoboken, New Jersey. Available at: http://www.cochrane.org/resources/handbook/hbook.htm. Last accessed on 6 September 2008.
14. Giardini A, Donti A, Formigari R, Salamone L, Palareti G, Guidetti D, Picchio FM. Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke. Cath Cardiovasc Interv 2006;67:625-629.
15. Morandi E, Anzola GP, Casilli F, Onorato E. Migraine: Traditional or "innovative" treatment? A preliminary case-control study. Pediatr Cardiol 2005;26:231-233.
16. Anzola GP, Frisoni GB, Morandi E, Casilli F, Onorato E. Shunt-associated migraine responds favorably to atrial septal repair. A case-control study. Stroke 2006;37:430-434.
17. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for hemodynamic reasons. Lancet 2000;356:1648-1651.
18. Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: A new migraine treatment?. J Interv Cardiol 2003;16:39-42. (Pubitemid 36293092)
19. Reisman M, Chistofferson RD, Jesurum J, Olsen JV, Spencer MP, Krabill KA, Diehl L, Aurora S, Gray WA. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005;45:493-495. (Pubitemid 40222239)
20. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R. Association of interatrial shunts and migraine headaches. Impact of transcatheter closure. J Am Coll Cardiol 2005;45: 489-492. (Pubitemid 40222238)
21. Mortelmans K, Post M, Thijs V, Herroelen L, Budts W. The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 2005;26:1533-1537. (Pubitemid 41373495)
22. Post MC, Thijs V, Herroelen L, Budts WIHL. Closure of patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004;62:1439-1440. (Pubitemid 38526070)
23. Schwerzmann M, Wiher S, Nedeltchev K, Mattle HP, Wahl A, Seiler C, Meier B, Windecker S. Percutaneous closure of patent foarmen ovale reduces the frequency of migraine attacks. Neurology 2004;62:1399-1401. (Pubitemid 38526056)
24. Giardini A, Donti A, Formigari R, Salomone L, Prandstaller D, Bonvicini M, Palareti G, Guidetti D, Gaddi O, Picchio FM. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. Am Heart J 2006;151:922.e1-922.e5.
25. Slavin L, Tobis JM, Rangarajan K, Dao C, Krivokapich J, Liebeskind DS. Five-year experience with percutaneous closure of patent foramen ovale. Am J Cardiol 2007;99:1316-1320. (Pubitemid 46659873)
26. Kimmelstiel C, Gange C, Thaler D. Is patent foramen ovale closure effective in reducing migraine symptoms? A controlled study. Catheter Cardiovasc Interv 2007;69:740-746. (Pubitemid 46581270)
27. Rigatelli G, Cardaioli P, Braggion G, Giordan M, Dell'avvocata F, Aggio S, Roncon L, Chinaglia M. Resolution of migraine by transcatheter patent foramen ovale closure by Premere occlusion system in a preliminary series of patients with previous cerebral ischemia. Catheter Cardiovasc Interv 2007;70:429-433.
28. Dubiel M, Brush L, Schmehl I, Liebner M, Winkelmann A, Stretz A, Grad MO, Kleber FX. Migraine headache relief after percutaneous transcatheter closure of interatrial communications. J Interv Cardiol 2008;21:32-37.
29. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Werlls C. Migraine intervention with STARFlex technology (MIST) trial. Circulation 2008;117:1397-1404.
30. Jesurum JT, Fuller CJ, Kim CJ, Krabill KA, Spencer MP, Olsen JV, Likosky WH, Reisman M. Frequency of migraine headache relief following patent foramen ovale "closure" despite residual right-to-left shunt. Am J Cardiol 2008;102:916-920.
31. Luermans J, Post MC, Temmerman F, Thijs V, Schonewille WJ, Plokker HWT, Suttorp MJ, Budts W. Closure of patent foramen ovale is associated with a decrease in prevalence of migraine: A prospective observational study. Acta Cardiol 2008;63:571-577.
32. Yankovsky AE, Kuritzky A. Transformation into daily migraine with aura following transcutaneous atrial defect closure. Headache 2003;43:496-498. (Pubitemid 36554665)
33. Jauss M, Zanette E. Detection of right-to-left shunt with ultrasound contrast agent and Doppler sonography. Cerebrovasc Dis 2000;10:490-496.
34. Fragoso YD. Reduction of migraine attacks during the use of warfarin. Headache 1997;37:667-668.
35. Buring JE, Peto R, Hennekens CH. Low dose aspirin for migraine prophylaxis. JAMA 1990;264:1711-1713.
36. Rahimtoola H, Egberts AC, Buurma H, Tijssen CC, Leufkens HG. Reduction in the intensity of abortive migraine drug use during cumarin therapy. Headache 2001;41:768-773. (Pubitemid 32953327)
37. Wilmshurst PT, Pearson MT, Nightingale S, Walsh KP, Morrison WL. Inheritance of persistent foamen ovale and atrial septal defects and relation to family migraine with aura. Heart 2004;90:1315-1320. (Pubitemid 39433997)
38. Van Der Kuy PH, Lohman JJ. A quantification of the placebo effect in migraine prophylaxis. Cephalalgia 2002;22:265-270.
39. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Clopidrogel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart 2005;91:1173-1175. (Pubitemid 41192391)
40. Khairy P, O'donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromoemboli. A systematic review. Ann Intern Med 2003;139:753-760.
41. Diener HC, Kurth T, Dodick D. Patent foramen ovale, stroke and cardiovascular disease in migraine. Curr Opin Neurol 2007;20:310-319. (Pubitemid 46743114)